Advancements in pharmacotherapy options for treating diabetes ‎in children and adolescents

References

• What is diabetes? International Diabetes Federation. https://idf.org/about-diabetes/what-is-diabetes/
   Google Scholar
• Ghanny S, Aisenberg J. Management of pediatric patients with type 1 diabetes. Pediatr Ann. 2014;43:115–120. doi: 10.3928/00904481-20140221-11
   PubMed Web of Science ®Google Scholar
• Dabelea D, Mayer-Davis EJ, Saydah S, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014;311:1778. doi: 10.1001/jama.2014.3201
   PubMed Web of Science ®Google Scholar
• IDF Diabetes Atlas. International Diabetes Federation; 2021.
   Google Scholar
• Calabria A Diabetes Mellitus in Children and Adolescents. MSD manual, professional version.
   Google Scholar
• Diabetes in children. Healthy Children.
   Google Scholar
• American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of Medical Care in diabetes—2019. Diabetes Care. 2019;42:S13–S28. doi: 10.2337/dc19-S002
   PubMed Web of Science ®Google Scholar
• Kalra S, Das AK, Bajaj S, et al. Utility of precision medicine in the management of diabetes: expert opinion from an International panel. Diabetes Ther. 2020;11:411–422. doi: 10.1007/s13300-019-00753-5
   PubMed Web of Science ®Google Scholar
• Montesanto A, Bonfigli AR, Crocco P, et al. Genes associated with type 2 diabetes and vascular complications. Aging. 2018;10:178–196. doi: 10.1863/2aging.101375
   PubMedGoogle Scholar
• Zeitler P, Arslanian S, Fu J, et al. ISPAD clinical practice consensus guidelines 2018: type 2 diabetes Mellitus in youth. Pediatr Diabetes. 2018;19:28–46. doi: 10.1111/pedi.12719
   PubMed Web of Science ®Google Scholar
• Delvecchio M, Mozzillo E, Salzano G, et al. Monogenic diabetes accounts for 6.3% of cases referred to 15 Italian pediatric diabetes centers from 2007 to 2012. The Journal Of Clinical Endocrinology & Metabolism. 2017;102(6):1826–1834.
   PubMed Web of Science ®Google Scholar
• Elder DA, Herbers PM, Weis T, et al. β-cell Dysfunction in adolescents and adults with newly diagnosed type 2 diabetes Mellitus. J Paediatr. 2012;160:904–910. doi: 10.1016/j.jpeds.2011.12.002
   PubMed Web of Science ®Google Scholar
• Pippitt K, Li M, Gurgle HE. Diabetes Mellitus: Screening and Diagnosis. Am Fam Physician. 2016;93(2):103–109.
   PubMed Web of Science ®Google Scholar
• Rodbard HW. Diabetes screening, diagnosis, and therapy in pediatric patients with type 2 diabetes. Medscape J Med. 2008;10:184. quiz 184
   PubMedGoogle Scholar
• Laffel LM, Kanapka LG, Beck RW, et al. Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial. JAMA. 2020;323:2388. doi: 10.1001/jama.2020.6940
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Ahn D, Drincic A. Continuous glucose monitoring: a review of the technology and clinical use. Diabet Res Clin Pract. 2017;133:178–192. doi: 10.1016/j.diabres.2017.08.005
   PubMed Web of Science ®Google Scholar
• Tabatabaei-Malazy O, Nikfar S, Larijani B, et al. Drugs for the treatment of pediatric type 2 diabetes Mellitus and related co-morbidities. Expert Opin Pharmacother. 2016;17:2449–2460. doi: 10.1080/14656566.2016.1258057
   PubMed Web of Science ®Google Scholar
• Becker M, Galler A, Raile K. Meglitinide analogues in adolescent patients with HNF1A-MODY (MODY 3). Pediatrics. 2014;133:e775–e779. doi: 10.1542/peds.2012-2537
   PubMed Web of Science ®Google Scholar
• Foughty ZC, Moryan-Blanchard K, Henkel EB, et al. Hyperosmolar hyperglycemic coma in an infant with neonatal diabetes Mellitus. Am J Emerg Med. 2022;54:327.e5–327.e6. doi: 10.1016/j.ajem.2021.10.026
   PubMedGoogle Scholar
• Mouler M, Lebenthal Y, de Vries L, et al. Clinical characteristics, growth patterns, and long-term diabetes complications of 24 patients with neonatal diabetes Mellitus: a single Center experience. Pediatr Diabetes. 2022;23:45–54. doi: 10.1111/pedi.13295
   PubMed Web of Science ®Google Scholar
• Juneja R, Hirsch IB, Naik RG, et al. Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1[Frac12] diabetes in patients presenting with type 2 diabetes. Metabolism. 2001;50:1008–1013. doi: 10.1053/meta.2001.25654
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of Medical Care in diabetes—2021. Diabetes Care. 2021;44:S15–S33. doi: 10.2337/dc21-S002
   PubMed Web of Science ®Google Scholar
• Fiasp. Novomedlink.
   Google Scholar
• Drugs and Lactation Database (LactMed), Insulin; National Library of Medicine (US)
   Google Scholar
• Wolfsdorf JI, Glaser N, Agus M, et al. ISPAD clinical practice consensus guidelines 2018: diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr Diabetes. 2018;19:155–177. doi: 10.1111/pedi.12701
   PubMed Web of Science ®Google Scholar
• Letourneau LR, Greeley SAW. Precision medicine: long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations. Curr Diab Rep. 2019;19(8):52. doi: 10.1007/s11892-019-1175-9
   PubMed Web of Science ®Google Scholar
• Lemelman MB, Letourneau L, Greeley SAW. Neonatal diabetes Mellitus. Clin Perinatol. 2018;45(1):41–59. doi: 10.1016/j.clp.2017.10.006
   PubMed Web of Science ®Google Scholar
• Bowman P, Sulen Å, Barbetti F, et al. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an International cohort study. Lancet Diabetes Endocrinol. 2018;6:637–646. doi: 10.1016/S2213-8587(18)30106-2
   PubMed Web of Science ®Google Scholar
• Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-Sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med. 2004;350(18):1838–1849.
   PubMed Web of Science ®Google Scholar
• Proks P, Arnold AL, Bruining J, et al. A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum Mol Genet. 2006;15:1793–1800. doi: 10.1093/hmg/ddl101
   PubMed Web of Science ®Google Scholar
• Zhang Z, Cao Y, Tao Y, et al. Sulfonylurea and fracture risk in patients with type 2 diabetes Mellitus: a meta‐analysis. Diabetes Res Clin Pract. 2020;159:107990. doi: 10.1016/j.diabres.2019.107990
   PubMed Web of Science ®Google Scholar
• Yahaya TO, Ufuoma SB. Genetics and pathophysiology of maturity-onset diabetes of the young (MODY): a review of Current trends. Oman Med J. 2020;35:e126–e126. doi: 10.5001/omj.2020.44
   PubMedGoogle Scholar
• Switching from insulin to sulfonylurea in diabetes associated with variants in MODY genes (SUtoChildt1d). Clinicaltrials.gov.
   Google Scholar
• Micronase-Approval Label.
   Google Scholar
• Thomas I, Gregg B. Metformin; a review of its history and future: from lilac to longevity: THOMAS and GREGG. Pediatr Diabetes. 2017;18:10–16. doi: 10.1111/pedi.12473
   PubMed Web of Science ®Google Scholar
• Fujita Y, Inagaki N. Metformin: new preparations and nonglycemic benefits. Curr Diab Rep. 2017;17:5. doi: 10.1007/s11892-017-0829-8
   PubMed Web of Science ®Google Scholar
• RIOMET-Approval Label.
   Google Scholar
• Foretz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol. 2023 Aug;19(8):460–476. doi: 10.1038/s41574-023-00833-4. Epub 2023 May 2. PMID: 37130947; PMCID: PMC10153049.
   Google Scholar
• Anderson JJA, Couper JJ, Giles LC, et al. Effect of metformin on vascular function in children with type 1 diabetes: a 12-month randomized controlled trial. The Journal Of Clinical Endocrinology & Metabolism. 2017;102(12):4448–4456. doi: 10.1210/jc.2017-00781
   PubMed Web of Science ®Google Scholar
• Al Khalifah RA, Alnhdi A, Alghar H, et al. The Effect of adding metformin to insulin therapy for type 1 diabetes Mellitus children: a systematic review and meta-analysis. Pediatr Diabetes. 2017;18:664–673. doi: 10.1111/pedi.12493
   PubMed Web of Science ®Google Scholar
• TODAY Study Group Effects of Metformin. Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY. Diabetes Care. 2013;36(6):1749–1757. doi: 10.2337/dc12-2393
   PubMed Web of Science ®Google Scholar
• Napoli C, Benincasa G, Schiano C, et al. Differential epigenetic factors in the prediction of cardiovascular risk in diabetic patients. Eur Heart J Cardiovasc Pharmacother. 2020;6:239–247. doi: 10.1093/ehjcvp/pvz062
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Schwartz GG, Nicholls SJ, et al. Effect of apabetalone on cardiovascular events in diabetes, CKD, and recent acute coronary syndrome: results from the BETonMACE randomized controlled trial. Clin J Am Soc Nephrol. 2021;16:705–716. doi: 10.2215/CJN.16751020
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Schwartz GG, Buhr KA, et al. Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study. Cardiovasc Diabetol. 2021;20:13. doi: 10.1186/s12933-020-01199-x
   PubMed Web of Science ®Google Scholar
• Sirdah MM, Reading NS. Genetic predisposition in type 2 diabetes: a promising approach toward a personalized management of diabetes. Clin Genet. 2020;98:525–547. doi: 10.1111/cge.13772
   PubMed Web of Science ®Google Scholar
• Prandin-Approval Label.
   Google Scholar
• Berger K. Meglitinides: uses, common brands, and safety info. 2022.
   Google Scholar
• Philip J, Fernandez CJ. Efficacy and cardiovascular safety of meglitinides. Curr Drug Saf. 2021;16:207–216. doi: 10.2174/1574886315666201026125848
   PubMed Web of Science ®Google Scholar
• Ryan PM, Seltzer S, Hayward NE, et al. Safety and efficacy of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity: a meta-analysis. J Pediatr. 2021;236:137–147.e13. doi: 10.1016/j.jpeds.2021.05.009
   PubMed Web of Science ®Google Scholar
• Page LC, Freemark M. Role of GLP-1 receptor agonists in pediatric obesity: benefits, risks, and approaches to patient selection. Curr Obes Rep. 2020;9:391–401. doi: 10.1007/s13679-020-00409-7
   PubMed Web of Science ®Google Scholar
• Victoza-Approval Label.
   Google Scholar
• Feingold KR. Oral and injectable (non-insulin) pharmacological agents for the treatment of type 2 diabetes. In: Feingold KR, Anawalt B, Boyce A, et al, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. PMID: 25905364.
   Google Scholar
• Phase 3 Alogliptin Pediatric Study. Clinicaltrials.gov.
   Google Scholar
• Dudkowski C, Tsai M, Liu J, et al. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes Mellitus. Eur J Clin Pharmacol. 2017;73:279–288. doi: 10.1007/s00228-016-2175-1
   PubMed Web of Science ®Google Scholar
• Tonouchi R, Mine Y, Aoki M, et al. Efficacy and safety of alogliptin in a pediatric patient with maturity-onset diabetes of the young type 1. Clin Pediatr Endocrinol. 2017;26:183–188. doi: 10.1297/cpe.26.183
   PubMedGoogle Scholar
• Subrahmanyan NA, Koshy RM, Jacob K, et al. Efficacy and cardiovascular safety of DPP-4 inhibitors. CDS. 2021;16(2):154–164. doi: 10.2174/1574886315999200819150544
   Google Scholar
• Mascolo A, Di Napoli R, Balzano N, et al. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: a brief summary. Front Cardiovasc Med. 2022;9:1010693. doi: 10.3389/fcvm.2022.1010693
   PubMed Web of Science ®Google Scholar
• Laffel LM, Danne T, Klingensmith GJ, et al. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, Double-blind, parallel group, phase 3 trial. Lancet Diabetes Endocrinol. 2023;11:169–181. doi: 10.1016/S2213-8587(22)00387-4
   PubMed Web of Science ®Google Scholar
• Tamborlane WV, Laffel LM, Shehadeh N, et al. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. Lancet Diabetes Endocrinol. 2022;10:341–350. doi: 10.1016/S2213-8587(22)00052-3
   PubMed Web of Science ®Google Scholar
• Colesevelam for children with type 2 diabetes (WELKid DM). Clinicaltrials.gov.
   Google Scholar
• Takebayashi K. Role of bile acid sequestrants in the treatment of type 2 diabetes. WJD. 2010;1:146. doi: 10.4239/wjd.v1.i5.146
   Google Scholar
• Fiorentino R, Chiarelli F. Treatment of dyslipidaemia in children. Biomedicines. 2021;9:1078. doi: 10.3390/biomedicines9091078
   PubMed Web of Science ®Google Scholar
• Rich SS, Cefalu WT. The impact of precision medicine in diabetes: a multidimensional perspective. Diabetes Care. 2016;39:1854–1857. doi: 10.2337/dc16-1833
   PubMed Web of Science ®Google Scholar
• Malandrino N, Smith RJ. Personalized medicine in diabetes. Clin Chem. 2011;57:231–240. doi: 10.1373/clinchem.2010.156901
   PubMed Web of Science ®Google Scholar
• Mohan V, Radha V. Precision diabetes is slowly becoming a reality. Med Princ Pract. 2019;28:1–9. doi: 10.1159/000497241
   PubMed Web of Science ®Google Scholar
• Manousaki D, Kent JW, Haack K, et al. Toward precision medicine: TBC1D4 disruption is common among the Inuit and leads to underdiagnosis of type 2 diabetes. Diabetes Care. 2016;39:1889–1895. doi: 10.2337/dc16-0769
   PubMed Web of Science ®Google Scholar
• Dujic T, Zhou K, Tavendale R, et al. Effect of serotonin transporter 5-HTTLPR polymorphism on gastrointestinal intolerance to metformin: a GoDARTS study. Diabetes Care. 2016;39(11):1896–1901. doi: 10.2337/dc16-0706
   PubMed Web of Science ®Google Scholar
• Dawed AY, Donnelly L, Tavendale R, et al. CYP2C8 and SLCO1B1 variants and therapeutic response to thiazolidinediones in patients with type 2 diabetes. Diabetes Care. 2016;39(11):1902–1908. doi: 10.2337/dc15-2464
   PubMed Web of Science ®Google Scholar
• Heianza Y, Ma W, Huang T, et al. Macronutrient intake–associated FGF21 genotype modifies effects of weight-loss diets on 2-year changes of central adiposity and body composition: the POUNDS lost trial. Diabetes Care. 2016;39:1909–1914. doi: 10.2337/dc16-1111
   PubMed Web of Science ®Google Scholar
• Ragia G, Petridis I, Tavridou A, et al. Presence of CYP2C9*3 allele increases risk for hypoglycemia in type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics. 2009;10:1781–1787. doi: 10.2217/pgs.09.96
   PubMed Web of Science ®Google Scholar
• Jerram ST, Dang MN, Leslie RD. The role of epigenetics in type 1 diabetes. Curr Diab Rep. 2017;17:89. doi: 10.1007/s11892-017-0916-x
   PubMed Web of Science ®Google Scholar
• Kim SY. Islet cell transplantation transitioning to proven therapy for type 1 diabetes. Ann Pediatr Endocrinol Metab. 2021 Jun;26(2):72–73. doi: 10.6065/apem.2121006edi02
   PubMed Web of Science ®Google Scholar
• Zaharia OP, Strassburger K, Strom A, et al. German Diabetes Study Group. Risk of diabetes-associated diseases in ‎subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lan Diab‎end. 2019 Sep;7(9):684–694. doi:10.1016/S2213-8587(19)30187-1. Epub 2019 Jul 22. PMID: 31345776.
   PubMed Web of Science ®Google Scholar
• Kariyawasam D, Morin C, Casteels K, et al. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial. Lancet Digit Health. 2022 Mar;4(3):e158–e168. doi: 10.1016/S2589-7500(21)00271-5
   PubMedGoogle Scholar
• Al-Beltagi M, Saeed NK, Bediwy AS, et al. Insulin pumps in children - a systematic review. World J Clin Pediatr. [2022 Nov 9];11(6):463–484. doi: 10.5409/wjcp.v11.i6.463
   PubMedGoogle Scholar
• Wadwa RP, Reed ZW, Buckingham BA, et al. Trial of Hybrid closed-loop control in young children with type 1 diabetes. N Engl J Med. [2023 Mar 16];388(11):991–1001. doi: 10.1056/NEJMoa2210834
   PubMed Web of Science ®Google Scholar